Glenmark Pharmaceutical Ltd.'s shares rose over 5% during trade on Monday, after the management highlighted a 300.2% sales ...

Glenmark Pharmaceuticals share price gained more than 5% during intraday trades on Monday post Q3 Results that were declared ...

Results: Glenmark Pharmaceuticals posted a net profit of ₹348 crore in Q3 FY25, reversing a ₹351 crore loss YoY. Revenue ...

VS Mani, CFO of Glenmark Pharma, discusses the company's strong performance in FY25 with an average of Rs 1,100 crore per ...

The revenue from operations at Glenmark Pharma during Q3FY25 also marked a 35.1 per cent year-on-year (YoY) rise to Rs ...

As the market opens for a new trading day, here are some stocks that are in focus. From BHEL’s new contract to Glenmark ...

Glenmark Pharmaceuticals Q3 Results 2025:Glenmark Pharmaceuticals declared their Q3 results on 14 Feb, 2025, revealing a ...

Glenmark Pharmaceuticals Ltd revenue from operations jumped 35.1% year-on-year to ₹3,387.6 crore, vs ₹2,506.7 crore during Q3 ...

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Clindamycin Phosphate Foam, 1%. Glenmark's Clindamycin ...

Glenmark Pharmaceuticals reported a consolidated profit after tax of Rs 348 crore in Q3 FY25, driven by strong regional ...

Glenmark Pharmaceuticals rose 5.7% after the company reported a 300.2% sales growth in India for the third quarter.

The company reported a loss of Rs 351 crore in the comparable quarter last year, hurt by sluggish sales in India and charges ...